Kodiak Sciences Inc (KOD) News
Filter KOD News Items
KOD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KOD News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest KOD News From Around the Web
Below are the latest news stories about KODIAK SCIENCES INC that investors may wish to consider to help them evaluate KOD as an investment opportunity.
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare ConferenceKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time. |
KOD Stock Rallies 271% in 6 Months on Eye Disease Program UpdatesKodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases. |
Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownershipKey Insights Significantly high institutional ownership implies Kodiak Sciences' stock price is sensitive to their... |
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025. |
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline PotentialKodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications. |
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades StockJefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on retinal (eye) diseases. Kodiak’s lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 trials, GLOW2 in diabetic retinopathy and DAYBREAK in patients with wet age-related macular degeneration (wet AMD). Both studies are actively enrolling patients. J |
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react? |
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in FocusKOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans. |
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsKodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. |
Kodiak Sciences to Participate in Upcoming Investor ConferencesKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. Members of the management team will also be available for one-on-one meetings. |